Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study

Mark Kozloff, Marianne Ulcickas Yood, Jordan Berlin, Patrick J. Flynn, Fairooz F. Kabbinavar, David M. Purdie, Mark A. Ashby, Wei Dong, Mary M. Sugrue, Axel Grothey

Research output: Contribution to journalArticle

251 Scopus citations

Abstract

Background. The Bevacizumab Regimens' Investigation of Treatment Effects (BRiTE) study is a prospective, observational cohort study designed to elucidate safety and effectiveness outcomes associated with bevacizumab combined with chemotherapy as used in clinical practice for first-line treatment of metastatic colorectal cancer (mCRC). Patients and Methods. Baseline characteristics, prespecified bevacizumab-related adverse events, and effectiveness data were collected from 1,953 mCRC patients who were receiving first-line treatment including bevacizumab at 248 U.S. sites. Results. At database lock, the median follow-up was 20.1 months. At baseline, 46% of patients were aged >65 years and 49% had an Eastern Cooperative Oncology Group performance status score >1. Fluorouracil, leucovorin, and oxaliplatin was the most common firstline chemotherapy regimen (56%). Overall rates of be-vacizumab-related adverse events in the BRiTE study, such as gastrointestinal perforation (1.9%), arterial thromboembolic events (2%), grade 3- 4 bleeding (2.2%), and de novo hypertension requiring medication (22%), were consistent with those reported in randomized clinical trials (RCTs) of bevacizumab in first-line mCRC treatment. The median progression-free survival (PFS) and overall survival (OS) times were 9.9 (95% confidence interval [CI], 9.5-10.3) months and 22.9 (95% CI, 21.9 -24.4) months, respectively. Conclusion. The median PFS and OS durations and safety profile of bevacizumab in the BRiTE study were similar to those in RCTs of bevacizumab plus chemotherapy in first-line mCRC patients. The observations from the BRiTE study complement and expand upon RCT data, providing clinical information in a large cohort of bevacizumab-treated patients and subgroups such as the elderly.

Original languageEnglish (US)
Pages (from-to)862-870
Number of pages9
JournalOncologist
Volume14
Issue number9
DOIs
StatePublished - Sep 1 2009

Keywords

  • Antiangiogenesis
  • Biologics
  • GI perforation
  • Registry
  • Systemic therapy
  • VEGF inhibition

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study'. Together they form a unique fingerprint.

  • Cite this

    Kozloff, M., Yood, M. U., Berlin, J., Flynn, P. J., Kabbinavar, F. F., Purdie, D. M., Ashby, M. A., Dong, W., Sugrue, M. M., & Grothey, A. (2009). Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study. Oncologist, 14(9), 862-870. https://doi.org/10.1634/theoncologist.2009-0071